PRODUCT NEWS

ELITechGroup – A Bruker Company launches the Candida auris ELITe MGB® Kit to support early screening and infection prevention 

  • The new IVDR-certified Real-Time PCR assay enables rapid molecular screening of Candida auris , supporting laboratories in strengthening infection prevention and control strategies. 

Turin, Italy – August 3, 2026 . ELITechGroup – A Bruker Company, announces the commercial launch of the Candida auris ELITe MGB® Kit, an IVDR-certified Real-Time PCR assay for the rapid molecular screening of  Candida auris  directly from axillary and groin swabs. 

As Candida Auris continues to emerge as a major healthcare-associated fungal pathogen worldwide, early identification of colonized patients has become increasingly important to support infection prevention and control programs. This new assay expands ELITechGroup’s molecular diagnostics portfolio with a standardized solution designed to help laboratories identify colonization rapidly and support timely clinical decision-making. 

Validated on the ELITe InGenius® and ELITe BeGenius® platforms, the Candida auris ELITe MGB® Kit provides a fully automated Sample-to-Result workflow, integrating nucleic acid extraction, Real-Time PCR amplification and result interpretation into a single streamlined process. 

The launch of the Candida auris ELITe MGB® Kit reinforces ELITechGroup’s commitment to delivering innovative molecular diagnostic solutions that support laboratories address emerging infectious threats through rapid, reliable and standardized testing. 

 

About Us 

ELITechGroup is part of Bruker Corporation and contributes to the Bruker Microbiology & Infection Diagnostics (BMID) division, developing cutting-edge technologies to support the evolving needs of clinical laboratories globally. 

Latest news

NEWSROOM

Validation of our Amoebiasis kits published in Journal of Clinical Microbiology

ELITechGroup Microbiology is pleased to announce that a recent study published in the Journal of Clinical Microbiology (DOI: 10.1128/jcm.00179-25) confirms the strong performance of the serological assays ELI.H.A Amoeba and ELITex Bicolor Amoeba, designed for the diagnosis of Entamoeba histolytica for amoebiasis infections. This evaluation compared four commercial assays across…

ELITechGroup Announces Regulatory Approval of its Blood Borne Virus Panel in Japan

ELITechGroup’s blood-borne virus (BBV) panel received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) The ELITe BBV panel was launched in 2022 and comprises three quantitative IVD assays targeting Human Immunodeficiency virus-1 (HIV-1), Human Hepatitis B Virus (HBV), and Human Hepatitis C Virus (HCV) Turin, June 13, 2024: ELITechGroup…

Let us help you

For general inquiries, please use the links to the right. The Contact link leads to a brief online form, and the Support link offers general phone and email information. Someone will be in touch with you soon.